Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): A randomised, multicentre, placebo-controlled study

The Lancet Haematology

Volumn 2, Issue 8, 2015, Pages e315-e325

  Bussel, James B ^a   De Miguel, Purificación Garcia ^b   Despotovic, Jenny M ^c   Grainger, John D ^d,e   Sevilla, Julián ^f   Blanchette, Victor S ^g   Krishnamurti, Lakshmanan ^h   Connor, Philip ⁱ   David, Michèle ^j   Boayue, Koh B ^k   Matthews, Dana C ^l   Lambert, Michele P ^m   Marcello, Lisa M ⁿ   Iyengar, Malini ⁿ   Chan, Geoffrey W ⁿ   Chagin, Karen D ⁿ   Theodore, Dickens ⁿ   Bailey, Christine K ⁿ   Bakshi, Kalpana K ⁿ  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^f HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

ⁱ UNIVERSITY OF WALES   (United Kingdom)

^j UNIVERSITY OF MONTREAL   (Canada)

^k UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^l SEATTLE CHILDREN S HOSPITAL   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; IMMUNOGLOBULIN; PLACEBO; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ADOLESCENT; ARTICLE; BONE MARROW EXAMINATION; CHILD; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INFANT; INTENTION TO TREAT ANALYSIS; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; AGONISTS; CANADA; CLINICAL TRIAL; FRANCE; NETHERLANDS; PRESCHOOL CHILD; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPAIN; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ADOLESCENT; BENZOATES; CANADA; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FRANCE; HUMANS; HYDRAZINES; INFANT; MALE; NETHERLANDS; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; SPAIN; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

EID: 84941354571     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00114-3     Document Type: Article

References (39)

1. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 33-40.
2. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-95.
3. Grainger JD, Rees JL, Reeves M, Bolton-Maggs PH. Changing trends in the UK management of childhood ITP. Arch Dis Child 2012; 97: 8-11.
4. Neunert CE, Buchanan GR, Imbach P, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 2013; 121: 4457-62.
5. Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 2003; 25: 660-64.
6. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
7. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-96.
8. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-207.
9. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703-07.
10. Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119: 5989-95.
11. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 2639-42.
12. Cooper N, Bussel JB. The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep 2010; 12: 94-100.
13. Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013; 98: 875-80.
14. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013; 121: 4782-90.
15. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Longterm risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 2014; 99: 392-98.
16. Klaassen RJ, Blanchette VS, Barnard D, et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools. J Pediatr 2007; 150: 510-5.
17. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33: 85-93.
18. Mitchell WB, Pinheiro MP, Boulad N, et al. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Am J Hematol 2014; 89: E228-34.
19. Ramaswamy K, Hsieh L, Leven E, Thompson MV, Nugent D, Bussel JB. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr 2014; 165: 600-05.
20. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.
21. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-47.
22. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebocontrolled trial. Lancet 2009; 373: 641-48.
23. Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 2015; published online July 29. http://dx.doi.org/10.1016/S0140-6736(15)61107-2.
24. George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009; 144: 409-15.
25. Klaassen RJ, Mathias SD, Buchanan Get al. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer 2012; 58: 395-98.
26. Grygiel JJ, Ward H, Ogborne M, Goldin A, Birkett DJ. Relationships between plasma theophylline clearance, liver volume and body weight in children and adults. Eur J Clin Pharmacol 1983; 24: 529-32.
27. Crom WR. Pharmacokinetics in the child. Environ Health Perspect 1994; 102 (suppl 11): 111-17.
28. Brynes R, Orazi A, Theodore D, Burgess P, Bailey CK, Thein MM, Bakshi KK. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia: Data from the EXTEND study. Am J Hematol 2015; published online March 19. DOI:10.1002/ajh.24011.
29. Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011; 155: 248-55.
30. Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66. patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica 2014; 99: 937-44.
31. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141: 683-88.
32. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 2007; 138: 245-48.
33. Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 2013; 121: 2596-606.
34. Bussel JB, Saleh MN, Wong RSM, et al. Update on the safety and efficacy of EXTENDed treatment with eltrombopag (EPAG) in adults with chronic immune thrombocytopenia (ITP). Blood 2013; 122: 2315 (abstr).
35. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121: 537-45.
36. Grainger J, Routledge D, Kruse A, et al. Thrombopoietin receptor agonists in paediatric ITP patients: long term follow up data in 34. patients. Blood 2014; 124: 4206 (abstr).
37. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86.
38. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118: 28-36.
39. Imbach P, Kuhne T, Muller D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46: 351-56.